Emerging drugs to treat squamous cell carcinomas of the head and neck

Bibliography

• Horner M, Ries L, Krapcho M, SEER Cancer Statistics Review, 1975-2006; 2009. Available from: http://seercancergov/csr/1975_2006/. [Accessed 31 March 2010]
   Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137-50
   PubMed Web of Science ®Google Scholar
• Boyle P, Levin B, editors. World Cancer Report 2008. WHO Press, Lyon; 2008
   Google Scholar
• Curado MP, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 2009;21(3):194-200
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005;103(9):1843-9
   PubMed Web of Science ®Google Scholar
• Hashibe M, Brennan P, Benhamou S, Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99(10):777-89
   PubMed Web of Science ®Google Scholar
• Hashibe M, Brennan P, Chuang SC, Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18(2):541-50
   PubMed Web of Science ®Google Scholar
• Lubin JH, Purdue M, Kelsey K, Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. Am J Epidemiol 2009;170(8):937-47
   PubMed Web of Science ®Google Scholar
• Purdue MP, Hashibe M, Berthiller J, Type of alcoholic beverage and risk of head and neck cancer – a pooled analysis within the INHANCE Consortium. Am J Epidemiol 2009;169(2):132-42
   PubMed Web of Science ®Google Scholar
• Negri E, Boffetta P, Berthiller J, Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 2009;124(2):394-401
   PubMed Web of Science ®Google Scholar
• Marron M, Boffetta P, Zhang ZF, Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 2010;39(1):182-96
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14(2):467-75
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9
   PubMed Web of Science ®Google Scholar
• Daling JR, Madeleine MM, Johnson LG, Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101(2):270-80
   PubMed Web of Science ®Google Scholar
• Heck JE, Berthiller J, Vaccarella S, Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2009;39(1):166-81
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005;114(5):806-16
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371(9625):1695-709
   PubMed Web of Science ®Google Scholar
• Wong RJ, Shah JP. The role of the head and neck surgeon in contemporary multidisciplinary treatment programs for advanced head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2010;18(2):79-82
   PubMed Web of Science ®Google Scholar
• Haigentz M Jr, Silver CE, Corry J, Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009;266(12):1845-55
   PubMed Web of Science ®Google Scholar
• Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4-14
   PubMed Web of Science ®Google Scholar
• Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol 2010;11(1):85-91
   PubMed Web of Science ®Google Scholar
• Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359(11):1143-54
   PubMed Web of Science ®Google Scholar
• Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation? Head Neck 2004;26(2):127-35
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology – Head and Neck Cancers V.1.2010; 2010
   Google Scholar
• Adelstein DJ, Li Y, Adams GL, An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92-8
   PubMed Web of Science ®Google Scholar
• Brizel DM, Albers ME, Fisher SR, Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798-804
   PubMed Web of Science ®Google Scholar
• Bensadoun RJ, Benezery K, Dassonville O, French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;64(4):983-94
   PubMed Web of Science ®Google Scholar
• Budach V, Stuschke M, Budach W, Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23(6):1125-35
   PubMed Web of Science ®Google Scholar
• Huguenin P, Beer KT, Allal A, Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22(23):4665-73
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8
   PubMed Web of Science ®Google Scholar
• Clark J, Li W, Smith G, Outcome of treatment for advanced cervical metastatic squamous cell carcinoma. Head Neck 2005;27(2):87-94
   PubMed Web of Science ®Google Scholar
• Ferrari D, Codeca C, Fiore J, A review on the treatment of relapsed/metastatic head and neck cancer. Expert Opin Pharmacother 2009;10(16):2625-32
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E, A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257-63
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Metch B, Schuller DE, Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10(8):1245-51
   PubMed Web of Science ®Google Scholar
• Adamo V, Ferraro G, Pergolizzi S, Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 2004;40(5):525-31
   PubMed Web of Science ®Google Scholar
• Basaran M, Bavbek SE, Gullu I, A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother 2002;14(2):207-13
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Leong T, Rowinsky E, Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19(4):1088-95
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562-7
   PubMed Web of Science ®Google Scholar
• Janinis J, Papadakou M, Xidakis E, Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000;23(2):128-31
   PubMed Web of Science ®Google Scholar
• Shin DM, Glisson BS, Khuri FR, Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16(4):1325-30
   PubMed Web of Science ®Google Scholar
• Shin DM, Khuri FR, Glisson BS, Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001;91(7):1316-23
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578-87
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5568-77
   PubMed Web of Science ®Google Scholar
• Mesia R, Rivera F, Kawecki A, Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010. [Epub ahead of print]
   Google Scholar
• Eli Lilly and Co. Fourth-Quarter and Full-Year 2009 Results. Indianapolis, Indiana; 2010. [28 January 2010]
   Google Scholar
• Bristol-Myers Squibb Fourth Quarter Earnings 2009 Results; 2010. [28 January 2010]
   Google Scholar
• Merck KgGA Business Results for 4th Quarter/Fiscal Year 2009; 2010. [23 February 2010]
   Google Scholar
• Zeng G. LLY: growth challenged over the near-term. Zacks Equity Research, Chicago, IL; 2010. [30 March 2010]
   Google Scholar
• Rowan K. Should cetuximab replace cisplatin in head and neck cancer? J Natl Cancer Inst 2010;102(2):74-6, 8
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-84
   PubMed Web of Science ®Google Scholar
• Bei R, Budillon A, Masuelli L, Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004;204(3):317-25
   PubMed Web of Science ®Google Scholar
• Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 2005;124(1):71-6
   PubMed Web of Science ®Google Scholar
• Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009;77(6):400-10
   PubMed Web of Science ®Google Scholar
• Cavalot A, Martone T, Roggero N, Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007;29(7):655-64
   PubMed Web of Science ®Google Scholar
• Ekberg T, Nestor M, Engstrom M, Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 2005;26(5):1177-85
   PubMed Web of Science ®Google Scholar
• Xia W, Lau YK, Zhang HZ, Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5(12):4164-74
   PubMed Web of Science ®Google Scholar
• Xia W, Lau YK, Zhang HZ, Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3(1):3-9
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Hua CH, Wan L, Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009;69(6):2568-76
   PubMed Web of Science ®Google Scholar
• Braut T, Krstulja M, Kujundzic M, Epidermal growth factor receptor protein expression and gene amplification in normal, hyperplastic, and cancerous glottic tissue: immunohistochemical and fluorescent in situ hybridization study on tissue microarrays. Croat Med J 2009;50(4):370-9
   PubMed Web of Science ®Google Scholar
• Kim S, Grandis JR, Rinaldo A, Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 2008;30(5):667-74
   PubMed Web of Science ®Google Scholar
• Grandis JR, Chakraborty A, Zeng Q, Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 1998;69(1):55-62
   PubMed Web of Science ®Google Scholar
• Liang K, Ang KK, Milas L, The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57(1):246-54
   PubMed Web of Science ®Google Scholar
• Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004;58(3):966-71
   PubMed Web of Science ®Google Scholar
• Dai Q, Ling YH, Lia M, Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005;11(4):1572-8
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27(11):1864-71
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Gooding WE, Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824-32
   PubMed Web of Science ®Google Scholar
• Temam S, Kawaguchi H, El-Naggar AK, Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25(16):2164-70
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170-6
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-6
   PubMed Web of Science ®Google Scholar
• Maurizi M, Almadori G, Ferrandina G, Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996;74(8):1253-7
   PubMed Web of Science ®Google Scholar
• Carter CA, Kelly RJ, Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 2009;18(12):1829-42
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Huang S, Vallabhaneni G, Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65(8):3328-35
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6(6):2166-74
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59(8):1935-40
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Zoccoli A, Pantano F, Cetuximab: from bench to bedside. Curr Cancer Drug Targets 2010;10(1):80-95
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Lee SC, Morgan S, Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58(11):1853-64
   PubMed Web of Science ®Google Scholar
• Taylor RJ, Chan SL, Wood A, FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009;58(7):997-1006
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133(12):1277-81
   PubMed Web of Science ®Google Scholar
• Iwase M, Takaoka S, Uchida M, Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. Oral Oncol 2008;44(4):361-8
   PubMed Web of Science ®Google Scholar
• Bozec A, Formento P, Ciccolini J, Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005;4(12):1962-71
   PubMed Web of Science ®Google Scholar
• Hirata A, Ogawa S, Kometani T, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62(9):2554-60
   PubMed Web of Science ®Google Scholar
• Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1(7):507-14
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Troiani T, Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001;93(2):172-8
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N, In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6(2):701-8
   PubMed Web of Science ®Google Scholar
• Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov 2006;5(12):987-8
   PubMed Web of Science ®Google Scholar
• Kim R. Cetuximab and panitumumab: are they interchangeable? Lancet Oncol 2009;10(12):1140-1
   PubMed Web of Science ®Google Scholar
• Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 2008;47(1):9-19
   PubMed Web of Science ®Google Scholar
• Kuenen B, Witteveen PO, Ruijter R, A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;16(6):1915-23
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Stockert E, Huang HJ, A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 2003;100(2):639-44
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Tebbutt N, A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007;104(10):4071-6
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-7
   PubMed Web of Science ®Google Scholar
• Cohen EE, Kane MA, List MA, Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11(23):8418-24
   PubMed Web of Science ®Google Scholar
• Caponigro F, Romano C, Milano A, A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs 2008;19(7):739-44
   PubMed Web of Science ®Google Scholar
• Chua DT, Wei WI, Wong MP, Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30(7):863-7
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Burris HA III, Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009;115(10):2138-46
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009;27(Suppl): 5s (abstract 6011)
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85
   PubMed Web of Science ®Google Scholar
• Siu LL, Soulieres D, Chen EX, Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25(16):2178-83
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Glisson BS, Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18S)(June 20 Supplement):6013
   Google Scholar
• delCampo J, Sebastian P, Hitt R, Results of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). 33rd ESMO Congress; 2008
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des 2009;15(4):345-52
   PubMed Web of Science ®Google Scholar
• Gerber PA, Hippe A, Buhren BA, Chemokines in tumor-associated angiogenesis. Biol Chem 2009;390(12):1213-23
   PubMed Web of Science ®Google Scholar
• Montag M, Dyckhoff G, Lohr J, Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships. Cancer Sci 2009;100(7):1210-8
   PubMed Web of Science ®Google Scholar
• Cortes-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol 2009;11(6):349-55
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005;11(4):1434-40
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2005;131(9):624-30
   PubMed Web of Science ®Google Scholar
• Neuchrist C, Erovic BM, Handisurya A, Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003;25(6):464-74
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Geleff S, Batistatou A, Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 2005;206(2):170-7
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Riedel F, Gotte K, Li M, Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int J Oncol 2003;23(3):577-83
   PubMed Web of Science ®Google Scholar
• Bock JM, Sinclair LL, Bedford NS, Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2008;134(4):355-62
   PubMed Web of Science ®Google Scholar
• Tong M, Lloyd B, Pei P, Mallery SR. Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem 2008;105(5):1202-10
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008;35(3):274-85
   PubMed Web of Science ®Google Scholar
• Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87(2):95-104
   PubMed Web of Science ®Google Scholar
• Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009;6(2):206-17
   PubMedGoogle Scholar
• Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005;18(4):485-94
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400
   PubMed Web of Science ®Google Scholar
• Cohen EE, Davis DW, Karrison TG, Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57
   PubMed Web of Science ®Google Scholar
• Cohen R, Stebbing J, Windsor A. Bevacizumab and surgery: what is the real risk? Future Oncol 2009;5(7):915-7
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8
   PubMed Web of Science ®Google Scholar
• Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13(13):3765-70
   PubMed Web of Science ®Google Scholar
• Williamson SK, Moon J, Huang CH, A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18S)(June 20 Supplement):6044
   Google Scholar
• Choong NW, Kozloff M, Taber D, Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2009. [Epub ahead of print]
   Google Scholar
• Machiels JP, Henry S, Zanetta S, Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28(1):21-8
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19(21):2474-88
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Stat3 as an oncogene. Cell 1999;98(3):295-303
   PubMed Web of Science ®Google Scholar
• Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003;63(14):3923-30
   PubMed Web of Science ®Google Scholar
• Hambek M, Baghi M, Strebhardt K, STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. Anticancer Res 2004;24(6):3881-6
   PubMed Web of Science ®Google Scholar
• Grandis JR, Drenning SD, Chakraborty A, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998;102(7):1385-92
   PubMed Web of Science ®Google Scholar
• Kijima T, Niwa H, Steinman RA, STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002;13(8):355-62
   PubMedGoogle Scholar
• Neiva KG, Zhang Z, Miyazawa M, Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 2009;11(6):583-93
   PubMed Web of Science ®Google Scholar
• Grandis JR, Drenning SD, Zeng Q, Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97(8):4227-32
   PubMed Web of Science ®Google Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6(10):587-95
   PubMed Web of Science ®Google Scholar
• Koppikar P, Choi SH, Egloff AM, Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14(13):4284-91
   PubMed Web of Science ®Google Scholar
• Nozawa H, Howell G, Suzuki S, Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 2008;14(13):4336-44
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11(19 Pt 1):6924-32
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Iida M, Kruser TJ, Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009;8(8):696-703
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009;28(43):3801-13
   PubMed Web of Science ®Google Scholar
• Lu Y, Li X, Liang K, Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007;67(17):8240-7
   PubMed Web of Science ®Google Scholar
• Brooks HD, Glisson B, Lu C, Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009;27(Suppl): 15s (abstract 6022)
   PubMed Web of Science ®Google Scholar
• Johnson FM, Agrawal S, Burris H, Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116(6):1582-91
   PubMed Web of Science ®Google Scholar
• Moral M, Paramio JM. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008;23(10):1269-78
   PubMed Web of Science ®Google Scholar
• Segrelles C, Moral M, Lara MF, Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 2006;25(8):1174-85
   PubMed Web of Science ®Google Scholar
• Pedrero JM, Carracedo DG, Pinto CM, Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114(2):242-8
   PubMed Web of Science ®Google Scholar
• Amornphimoltham P, Sriuranpong V, Patel V, Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;10(12 Pt 1):4029-37
   PubMed Web of Science ®Google Scholar
• Wu Z, Gioeli D, Conaway M, Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008;68(9):935-44
   PubMed Web of Science ®Google Scholar
• Jhawer M, Goel S, Wilson AJ, PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68(6):1953-61
   PubMed Web of Science ®Google Scholar
• Aissat N, Le Tourneau C, Ghoul A, Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62(2):305-13
   PubMed Web of Science ®Google Scholar
• McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses. Virus Res 2009;143(2):195-208
   PubMed Web of Science ®Google Scholar
• Nishioka S, Fukushima K, Nishizaki K, Human papillomavirus as a risk factor for head and neck cancers – a case-control study. Acta Otolaryngol Suppl 1999;540:77-80
   PubMedGoogle Scholar
• Strome SE, Savva A, Brissett AE, Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002;8(4):1093-100
   PubMed Web of Science ®Google Scholar
• Chen PC, Kuo C, Pan CC, Chou MY. Risk of oral cancer associated with human papillomavirus infection, betel quid chewing, and cigarette smoking in Taiwan – an integrated molecular and epidemiological study of 58 cases. J Oral Pathol Med 2002;31(6):317-22
   PubMed Web of Science ®Google Scholar
• Smith EM, Ritchie JM, Summersgill KF, Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004;96(6):449-55
   PubMed Web of Science ®Google Scholar
• Mork J, Lie AK, Glattre E, Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344(15):1125-31
   PubMed Web of Science ®Google Scholar
• Herrero R, Castellsague X, Pawlita M, Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95(23):1772-83
   PubMed Web of Science ®Google Scholar
• Hammarstedt L, Lindquist D, Dahlstrand H, Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119(11):2620-3
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342-50
   PubMed Web of Science ®Google Scholar
• Scheffner M, Werness BA, Huibregtse JM, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63(6):1129-36
   PubMed Web of Science ®Google Scholar
• Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75(3):495-505
   PubMed Web of Science ®Google Scholar
• Kessis TD, Slebos RJ, Nelson WG, Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90(9):3988-92
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243(4893):934-7
   PubMed Web of Science ®Google Scholar
• Munger K, Werness BA, Dyson N, Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989;8(13):4099-105
   PubMed Web of Science ®Google Scholar
• Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101(6):412-23
   PubMed Web of Science ®Google Scholar
• Strati K, Lambert PF. Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res 2007;67(24):11585-93
   PubMed Web of Science ®Google Scholar
• Gillison ML, DSouza G, Westra W, Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100(6):407-20
   PubMed Web of Science ®Google Scholar
• Kies MS, Holsinger FC, Lee JJ, Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010;28(1):8-14
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100(4):261-9
   PubMed Web of Science ®Google Scholar
• Nichols AC, Faquin WC, Westra WH, HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009;140(2):228-34
   PubMed Web of Science ®Google Scholar
• Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121(8):1813-20
   PubMed Web of Science ®Google Scholar
• Licitra L, Perrone F, Bossi P, High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24(36):5630-6
   PubMed Web of Science ®Google Scholar
• Westra WH, Taube JM, Poeta ML, Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008;14(2):366-9
   PubMed Web of Science ®Google Scholar
• Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010;109(1):4-24
   PubMed Web of Science ®Google Scholar
• Baleja JD, Cherry JJ, Liu Z, Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 2006;72(1):49-59
   PubMed Web of Science ®Google Scholar
• Jung SO, Ro HS, Kho BH, Surface plasmon resonance imaging-based protein arrays for high-throughput screening of protein–protein interaction inhibitors. Proteomics 2005;5(17):4427-31
   PubMed Web of Science ®Google Scholar
• Butz K, Denk C, Ullmann A, Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000;97(12):6693-7
   PubMed Web of Science ®Google Scholar
• Sterlinko Grm H, Weber M, Elston R, Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J Mol Biol 2004;335(4):971-85
   PubMed Web of Science ®Google Scholar
• Beerheide W, Bernard HU, Tan YJ, Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J Natl Cancer Inst 1999;91(14):1211-20
   PubMed Web of Science ®Google Scholar
• Beerheide W, Sim MM, Tan YJ, Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg Med Chem 2000;8(11):2549-60
   PubMed Web of Science ®Google Scholar
• Machtay M, Moughan J, Trotti A, Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26(21):3582-9
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007;25(26):4096-103
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Atasoy BM, Daley FM, Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23(24):5560-7
   PubMed Web of Science ®Google Scholar
• Eriksen JG, Steiniche T, Askaa J, The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004;58(2):561-6
   PubMed Web of Science ®Google Scholar
• Han SW, Kim TY, Hwang PG, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23(11):2493-501
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Endoh H, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23(11):2513-20
   PubMed Web of Science ®Google Scholar
• Taron M, Ichinose Y, Rosell R, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11(16):5878-85
   PubMed Web of Science ®Google Scholar
• Ruiz-Godoy RL, Garcia-Cuellar CM, Herrera Gonzalez NE, Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J Exp Clin Cancer Res 2006;25(1):73-8
   PubMed Web of Science ®Google Scholar
• Yarbrough WG, Shores C, Witsell DL, Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104(11 Pt 1):1337-47
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66(8):3992-5
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK, Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55(14):3140-8
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27(28):3944-56
   PubMed Web of Science ®Google Scholar
• Cooper JB, Cohen EE. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck 2009;31(8):1086-94
   PubMed Web of Science ®Google Scholar
• Sisk EA, Soltys SG, Zhu S, Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 2002;24(9):841-9
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar